At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
Comparator: Estrace 0.5 mg +2 moredrug
Likely dose
Comparator: Estrace 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Clinical Trial to Evaluate the Effects of Estrogen on Uterine Endometrium in Healthy Postmenopausal Women
In Brief
A Phase 1 clinical trial evaluating Comparator: Estrace 0.5 mg, Comparator: Estrace 2 mg, and 1 other intervention for Postmenopausal Symptoms. Completed, enrolled 29 participants.
Detailed Summary
The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining (endometrium).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Symptoms
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedJan 2009
Primary CompletionMay 2009
TodayJul 2026
First PostedJan 12, 2009
Enrollment StartDec 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.5 years ago
Interventions
Comparator: Estrace 0.5 mgdrug
0.5 mg tablet taken once daily for 28 days
Comparator: Estrace 2 mgdrug
2 mg tablets taken once daily for 28 days.
Comparator: Placebodrug
Placebo 0 mg capsule taken once daily for 28 days